GAL and liver cancer: Similarly to the previous therapeutic effect evaluation model, we confirmed liver cancer development and injected the C12-SPM-siRNA mix or C12-SPM-GAL-siRNA mix weekly into the tail vein, with intraperitoneal sorafenib serving as a positive control.